

**Ongoing Cardiovascular Outcomes Trial (CVOT) Timeline - July 19, 2018**

- The table below includes an overview of ongoing cardiovascular outcomes trials (CVOTs). It includes all of the ongoing CVOTs related to diabetes drugs or PCSK9 inhibitors that we are aware of, though we acknowledge that it may be incomplete. We will continuously update the table as timelines change.

<b>Molecule</b>	<b>Name of Clinical Trial</b>	<b>Class of Drug</b>	<b>Study Enrollment</b>	<b>Primary Outcome Measures</b>	<b>Expected Completion Date</b>
Tradjenta/Trajenta (linagliptin) vs. glimepiride	CAROLINA	DPP-4 inhibitor vs. sulfonylurea	6,115	4-point MACE composite endpoint (CV death, non-fatal MI, non-fatal stroke, and hospitalization for unstable angina)	<a href="#">August 2018</a>
Steglatro (ertugliflozin)	VERTIS CV	SGLT-2 inhibitor	8,000	3-point MACE composite endpoint (CV death, non-fatal MI, non-fatal stroke)	<a href="#">September 2019</a>
Farxiga (dapagliflozin) in HFpEF	Dapa-HF	SGLT-2 inhibitor	4,744	composite of CV death, hospitalization for heart failure, or urgent HF visit	<a href="#">December 2019</a>
Jardiance (empagliflozin) in HFpEF	EMPEROR-Preserved	SGLT-2 inhibitor	4,126	composite of CV death or hospitalization for heart failure	<a href="#">June 2020</a>

Jardiance (empagliflozin) in HFrEF	EMPEROR-Reduced	SGLT-2 inhibitor	2,850	composite of CV death or hospitalization for heart failure	<a href="#">June 2020</a>
Farxiga (dapagliflozin) in CKD	Dapa-CKD	SGLT-2 inhibitor	4,000	Composite of (i) ≥50% sustained decline in eGFR, (ii) reaching ESRD, and (iii) CV or renal death	<a href="#">November 2020</a>
sotagliflozin	SOLOIST-WHF	SGLT-1/2 dual inhibitor	4,000	composite of CV death or hospitalization for heart failure	<a href="#">January 2021</a>
Farxiga (dapagliflozin) in HFpEF	DELIVER	SGLT-2 inhibitor	4,700	composite of CV death, hospitalization for heart failure, or urgent HF visit	<a href="#">June 2021</a>
sotagliflozin	SCORED	SGLT-1/2 dual inhibitor	10,500	3-point MACE composite (CV death, non-fatal MI, non-fatal stroke); CV death/hospitalization for heart failure composite	<a href="#">March 2022</a>
Jardiance (empagliflozin) in CKD	EMPA-KIDNEY	SGLT-2 inhibitor	5,000	Composite of (i) CKD progression - ESKD, decline in eGFR to <10 mL/min/1.73m <sup>2</sup> , renal death, or a	<a href="#">June 2022</a>

				sustained decline of $\geq 40\%$ in eGFR from randomization, and (ii) CV death	
semaglutide for obesity	SELECT	GLP-1 agonist	17,500	3-point MACE composite (CV death, non-fatal MI, non-fatal stroke)	<a href="#">September 2023</a>
oral semaglutide	"SOUL 2"	oral GLP-1 agonist	unknown	unknown	unknown